Urologic malignancies: advances in the analysis and interpretation of clinical findings.
作者信息
Crocetto Felice, Buonerba Carlo, Caputo Vincenzo, Ferro Matteo, Persico Francesco, Trama Francesco, Iliano Ester, Rapisarda Sebastiano, Bada Maida, Facchini Gaetano, Verde Antonio, Placido Sabino De, Barone Biagio
机构信息
Department of Neurosciences, Human Reproduction & Odontostomatology, University of Naples Federico II, Naples 80131, Italy.
Department of Oncology & Hematology, Regional Reference Center for Rare Tumors, AOU Federico II of Naples, Naples 80131, Italy.
出版信息
Future Sci OA. 2021 Feb 4;7(4):FSO674. doi: 10.2144/fsoa-2020-0210.
Abstract
摘要
相似文献
1
Urologic malignancies: advances in the analysis and interpretation of clinical findings.
Future Sci OA. 2021 Feb 4;7(4):FSO674. doi: 10.2144/fsoa-2020-0210.
2
Cancer immunotherapy: new applications in urologic oncology.
Curr Opin Urol. 2016 Nov;26(6):556-63. doi: 10.1097/MOU.0000000000000337.
3
Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies.
Semin Oncol. 2020 Dec;47(6):367-379. doi: 10.1053/j.seminoncol.2020.09.002. Epub 2020 Oct 24.
4
Cancer immunotherapy: new applications in urologic oncology.
Curr Opin Urol. 2016 Nov;26(6):535-42. doi: 10.1097/MOU.0000000000000345.
5
The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignancies.
Chin J Cancer Res. 2015 Apr;27(2):128-37. doi: 10.3978/j.issn.1000-9604.2014.12.15.
6
Vaccines in urologic malignancies.
Urol Res. 2001 Jun;29(3):152-62. doi: 10.1007/s002400100178.
7
Cutaneous metastases from genitourinary malignancies.
Urology. 2004 Jun;63(6):1021-6. doi: 10.1016/j.urology.2004.01.014.
8
Association between urologic malignancies and end-stage renal disease: A meta-analysis.
Nephrology (Carlton). 2019 Jan;24(1):65-73. doi: 10.1111/nep.13209.
9
The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
Eur Urol. 2017 Feb;71(2):237-246. doi: 10.1016/j.eururo.2016.08.024. Epub 2016 Aug 25.
10
Urologic de novo malignancies after kidney transplantation: a single center experience.
Transplant Proc. 2012 Jun;44(5):1293-7. doi: 10.1016/j.transproceed.2011.11.063.
引用本文的文献
1
Liquid Biopsy: Current advancements in clinical practice for bladder cancer.
J Liq Biopsy. 2025 Jul 8;9:100310. doi: 10.1016/j.jlb.2025.100310. eCollection 2025 Sep.
2
Improvements in the prognosis of patients with stage IV renal cancer according to the era of therapeutic agents: an analysis of National Cancer Registry data.
Transl Androl Urol. 2025 Jun 30;14(6):1734-1741. doi: 10.21037/tau-2025-163. Epub 2025 Jun 26.
3
From infection to tumor: genetic evidence of viral antibody immune response' role in urologic cancer development.
Discov Oncol. 2025 May 29;16(1):947. doi: 10.1007/s12672-025-02768-w.
4
Effect of prostate volume on the predictive value of prostate-specific antigen density for prostate cancer.
Transl Androl Urol. 2025 Jan 31;14(1):70-80. doi: 10.21037/tau-24-490. Epub 2025 Jan 22.
5
Construction of a clinically significant prostate cancer risk prediction model based on traditional diagnostic methods.
Front Oncol. 2024 Dec 20;14:1474891. doi: 10.3389/fonc.2024.1474891. eCollection 2024.
6
The Correlation Between Body Mass Index and Prostate Volume: A Retrospective Analysis of Pre and Postoperative Measurements in Prostate Cancer Patients.
Prostate. 2025 Apr;85(5):433-442. doi: 10.1002/pros.24845. Epub 2024 Dec 23.
7
Quality by design: how poor adherence to guidelines holds back urological app innovation.
J Basic Clin Physiol Pharmacol. 2024 Dec 13;36(1):1-2. doi: 10.1515/jbcpp-2024-0205. eCollection 2025 Jan 1.
8
A Pilot Study of the Role of Semaphorin 4A (sema4A) and 3C (sema3C) in Non-Muscle-Invasive Bladder Cancer (NMIBC).
Biomedicines. 2024 Oct 21;12(10):2407. doi: 10.3390/biomedicines12102407.
9
Assessing muscle invasion in bladder cancer via virtual biopsy: a study on quantitative parameters and classical radiomics features from dual-energy CT imaging.
BMC Med Imaging. 2024 Sep 16;24(1):245. doi: 10.1186/s12880-024-01427-w.
10
Exploring the Multifactorial Landscape of Penile Cancer: A Comprehensive Analysis of Risk Factors.
Diagnostics (Basel). 2024 Aug 16;14(16):1790. doi: 10.3390/diagnostics14161790.
本文引用的文献
1
First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings.
Crit Rev Oncol Hematol. 2021 Jan;157:103198. doi: 10.1016/j.critrevonc.2020.103198. Epub 2020 Dec 13.
2
Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2021 Mar;32(3):422-423. doi: 10.1016/j.annonc.2020.11.016. Epub 2020 Nov 30.
3
The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Eur Urol. 2021 Jun;79(6):783-792. doi: 10.1016/j.eururo.2020.10.006. Epub 2020 Nov 7.
4
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med. 2020 Dec 10;383(24):2345-2357. doi: 10.1056/NEJMoa2022485. Epub 2020 Sep 20.
5
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
N Engl J Med. 2020 Sep 24;383(13):1218-1230. doi: 10.1056/NEJMoa2002788. Epub 2020 Sep 18.
6
Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis.
Dis Markers. 2020 Jun 27;2020:8375348. doi: 10.1155/2020/8375348. eCollection 2020.
7
Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
Crit Rev Oncol Hematol. 2020 Jul;151:102992. doi: 10.1016/j.critrevonc.2020.102992. Epub 2020 May 23.
8
Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Cancers (Basel). 2020 Feb 10;12(2):408. doi: 10.3390/cancers12020408.
9
Cancer statistics, 2020.
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
10
The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.
Drugs. 2019 Mar;79(4):381-400. doi: 10.1007/s40265-019-1060-5.
Zotero 插件